Rituximab-induced serum sickness in a patient with follicular lymphoma [3]

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1633-1635

  Disperati, P ^a   Hicks, L K ^b   Buckstein, R ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUOXETINE; METHYLPREDNISOLONE SODIUM SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PARACETAMOL; PETHIDINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTHRALGIA; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FACE EDEMA; FEMALE; FEVER; FLUSHING; FOLLICULAR LYMPHOMA; GASTROESOPHAGEAL REFLUX; HEART DILATATION; HUMAN; JOINT SWELLING; LABORATORY TEST; LETTER; MULTIPLE CYCLE TREATMENT; MYALGIA; PERICARDIAL EFFUSION; PERICARDITIS; PRIORITY JOURNAL; PRURITUS; SERUM SICKNESS; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; THORAX PAIN;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; PREDNISOLONE; SERUM SICKNESS; TREATMENT OUTCOME; VINCRISTINE;

EID: 34547975183     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701441752     Document Type: Letter

References (13)

1. D'Arcy, C. A. and Mannik, M. (2001) Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum, 44, pp. 1717-1718.
2. Herishanu, Y. (2002) Rituximab-induced serum sickness. Am J Hematol, 70, p. 329.
3. Hellerstedt, B. and Ahmed, A. (2003) Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol, 14, p. 1792.
4. Catuogno, M., Rezai, S., Priori, R., Magrini, L. and Valesini, G. (2005) Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford), 44, p. 406.
5. Wang, J., Wiley, J. M., Luddy, R., Greenberg, J., Feuerstein, M. A. and Bussel, J. B. (2005) Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment. J Pediatr, 146, pp. 217-221.
6. Pijpe, J., van Imhoff, G. W., Spijkervet, F. K., Roodenburg, J. L., Wolbink, G. J. and Mansour, K. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study. Arthritis Rheum, 52, pp. 2740-2750.
7. Bennett, C. M., Rogers, Z. R., Kinnamon, D. D., Bussel, J. B., Mahoney, D. H. and Abshire, T. C. (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 107, pp. 2639-2642.
8. Seror, R., Sordet, C., Guillevin, L., Hachulla, E., Masson, C. and Ittah, M. (2006) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis
9. Devauchelle-Pensec, V., Pennec, Y., Morvan, J., Pers, J. O., Daridon, C. and Jousse-Joulin, S. (2007) Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum, 57, pp. 310-317.
10. Finger, E. and Scheinberg, M. (2007) Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol, 13, pp. 94-95.
11. Schutgens, R. E. (2006) Rituximab-induced serum sickness. Br J Haematol, 135, p. 147.
12. Portlock, C. S., O'Connor, O. A., Straus, D. J., Rosenzweig, L., Dumitrescu, O. and Lin, O. (2006) Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation?. Leuk Lymphoma, 47, pp. 1260-1264.
13. Todd, D. J. and Helfgott, S. M. (2007) Serum sickness following treatment with rituximab. J Rheumatol, 34, pp. 430-433.